Dr Reddy's files FY2026 Integrated Annual Report, BRSR, and AGM notice
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty 100 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr Reddy's has submitted its Integrated Annual Report, Business Responsibility and Sustainability Report (BRSR), and 42nd AGM notice for FY2025-26 to stock exchanges, sent electronically to members. Key highlights: revenue at Rs 3,35,933 mn (up 3.2%), EBITDA margin of 22.8% impacted by expected lenalidomide decline and one-off items including inventory adjustments, provisions, and impairment charges. India formulations grew 16%. Total 220 new product launches globally during the year.
Routine annual filing provides transparency on FY2026 results. EBITDA margin compressed YoY due to one-off charges, though underlying business stays resilient with strong India growth.